MedPath

Betaine

Generic Name
Betaine
Brand Names
Amversio, Cystadane, EnBrace HR, EnLyte
Drug Type
Small Molecule
Chemical Formula
C5H11NO2
CAS Number
107-43-7
Unique Ingredient Identifier
3SCV180C9W

Overview

Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Currently, no treatments are available to correct the genetic causes of homocystinuria. However, in order to normalize homocysteine levels, patients can be treated with vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and specific diets. Betaine reduces plasma homocysteine levels in patients with homocystinuria. Although it is present in many food products, the levels found there are insufficient to treat this condition. The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria, and the EMA has approved the use of Amversio (betaine anhydrous, oral powder).

Background

Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Currently, no treatments are available to correct the genetic causes of homocystinuria. However, in order to normalize homocysteine levels, patients can be treated with vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and specific diets. Betaine reduces plasma homocysteine levels in patients with homocystinuria. Although it is present in many food products, the levels found there are insufficient to treat this condition. The FDA and EMA have approved the product Cystadane (betaine anhydrous, oral solution) for the treatment of homocystinuria, and the EMA has approved the use of Amversio (betaine anhydrous, oral powder).

Indication

Betaine is indicated for the treatment of homocystinuria in pediatric and adult patients to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl).

Associated Conditions

  • Homocystinuria
  • Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
  • Homocystinuria due to MTHFR deficiency
  • Homocystinuria due to cobalamin cofactor metabolism (cbl) defect

FDA Approved Products

Betaine Anhydrous
Manufacturer:Eton Pharmaceuticals, Inc.
Route:ORAL
Strength:1 g in 1 g
Approved: 2023/12/18
NDC:71863-115
Betaine Anhydrous for Oral Solution
Manufacturer:OAKRUM PHARMA, LLC
Route:ORAL
Strength:1 g in 1 g
Approved: 2022/11/10
NDC:72647-900
Cystadane
Manufacturer:Orphan Europe SARL
Route:ORAL
Strength:1 g in 1 g
Approved: 2018/03/05
NDC:52276-401
Cystadane
Manufacturer:Recordati Rare Diseases
Route:ORAL
Strength:1 g in 1 g
Approved: 2023/01/11
NDC:52276-400
Betaine
Manufacturer:Cosette Pharmaceuticals, Inc.
Route:ORAL
Strength:1 g in 1 g
Approved: 2022/11/04
NDC:0713-0352

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath